Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets.
July 13, 2015
Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two … [Read More...]
June 29, 2015
Blueprint Medicines Added to Russell 2000®, 3000® and Global Indexes … [Read More...]